Investigation of rate+extent of excretion of radioactivity in urine+faeces after oral administration of [14C]AZD1386
Study identifier:D5090C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open, Single dose, Phase I study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics following Oral administration of [14C]AZD1386 to Healthy Male Volunteers
Medical condition
Pain
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1386
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
35 Years - 50 Years
Date
Study Start Date: 01 Jan 2009
Primary Completion Date: -
Study Completion Date: 01 Feb 2009
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
N/A
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1386 1 dose of oral solution Other Name: N/A |
Contacts
Investigators
Principal Investigator
Raj Chetty
AstraZeneca R&D, CPU Alderley Park, UK
